The latest trend in treating hair loss may sound familiar — essentially, it's a repurposed drug first popularized in the ...

Cube will underpin many of the AI tools we will develop in the years to come, including highly complex scene-generation tools ...

Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) shares shot up 2.1% during trading on Wednesday after Bank of America raised their price target on the stock from $21.00 to $22.00. Bank of ...

Copycat versions of Eli Lilly’s diabetes drug Mounjaro and obesity drug Zepbound were supposed to go away this week. They’re ...

In the public imagination, ETFs have long been typecast as staid, index-tracking products designed to help investors build ...

Globus Medical GMED has experienced strong upward momentum in the past year, with its shares rising 41.8%. This has far outpaced the industry’s 7.5% decline and the S&P 500 composite’s 8.8% growth.

This year, expect things to get a little bit crunchier. Cleanses, supplements, gut health—the terminology and trends once ...

Getting older has a few perks — wisdom, greater perspective on life and senior discounts among them — but most of us ...

As the U.S. stock market shows signs of stabilizing with the S&P 500 and Nasdaq attempting to break their recent losing streaks, investors are keenly observing companies that demonstrate resilience ...

Eli Lilly (LLY) launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk (NVO) for a much-awaited entry into the world’s most populous country ...

Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects ...